



02-27-03

GP/1635 P

Express Mail No.: EL539792295US

**HOWREY SIMON ARNOLD & WHITE, LLP**  
301 Ravenswood Avenue, Box 34  
Menlo Park, CA 94025  
(650) 463-8100

FORM PTO-1083

Attorney Docket No.: 03678.0103.CPUS00

In re application of:

Jose L. Boyer, et al.  
Appl. No.: 10/087,551  
Filed: February 27, 2003  
Confirmation No.: 6893

**RECEIVED**

MAR 06 2003

For: **COMPOSITIONS AND METHODS FOR THE TREATMENT OF GLAUCOMA AND OCULAR HYPERTENSION**  
*TECH CENTER 1600/2900*

COMMISSIONER FOR PATENTS  
Washington, D.C. 20231

Sir:

Transmitted herewith is the following in the above-identified application.

1. PTO Form 1083 (1 pg.);
2. Request to Amend Priority Claim (1 pg.);
3. Request to Correct Inventorship Under 37 C.F.R. §1.48(a) (2 pgs.);
4. Combined Declaration and Power of Attorney (4 pgs.);
5. Consent of Assignee To Add An Inventor (1 pg.);
6. Statement From Inventor Being Added (1 pg.); and
7. Check for \$130.00 for fee as set forth in §1.17(i).

■ The U.S. Patent and Trademark Office is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 08-3038 referencing docket number 03678.0103.CPUS00. A duplicate copy of this sheet is attached.

*Albert P. Halluin*  
Albert P. Halluin (Reg. No. 25,227)  
Viola T. Kung (Reg. No. 41,131)

Date: February 25, 2003

HOWREY SIMON ARNOLD & WHITE, LLP  
Box No. 34  
301 Ravenswood Ave.  
Menlo Park, CA 94025  
(650) 463-8109



EXPRESS MAIL NO.: EL539792295US

RECEIVED #8  
5-5-03

MAR 06 2003

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Jose L. Boyer, *et al.*

Appl. No. 10/087,551

Filed: February 27, 2002

For: **COMPOSITIONS AND METHODS  
FOR THE TREATMENT OF  
GLAUCOMA AND OCULAR  
HYPERTENSION**

Art Unit: 1635

Examiner: Not Yet Assigned

Attorney Docket: 03678.0103.CUPS00

Confirmation No.: 6893

**REQUEST TO CORRECT INVENTORSHIP UNDER 37 C.F.R. §1.48(a)**

Commissioner for Patents  
Washington D.C. 20231

Sir:

Applicants are submitting a request to correct inventorship under 37 CFR §1.48(a) to correct inventorship. Applicants request to amend the application to add James G. Douglass, III, as an inventor. The correct inventive entity is Jose L. Boyer, Benjamin R. Yerxa, Robert Plourde, Jr., Edward G. Brown, and James G. Douglass, III.

The inventive entity in the Inventor Declaration executed on May 8 and 9, 2002 was set forth in error; such error arose without any deceptive invention on the part of James G. Douglass, III, who through error was not named as an inventor.

According to 37 CFR § 1.48(a), this Request is accompanied by:


- (a) A statement form Mr. Douglass that the error in inventorship occurred without deceptive intention on his part;
- (b) A declaration by the actual inventors as required by § 1.63;
- (c) The fee set forth in § 1.17(i);
- (d) The written consent of the assignee.

Respectfully submitted,

Date: February 25, 2003

  
Albert P. Halluin (Reg. No. 25,227)  
Viola T. Kung (Reg. No. 41,131)

**HOWREY SIMON ARNOLD & WHITE, LLP**  
Box 34  
301 Ravenswood Avenue  
Menlo Park, CA 94025  
Telephone: (650) 463-8109



109

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Jose L. BOYER, *et al.*

Appl. No. 10/087,551

Art Unit: 1635

Examiner: Not Yet Assigned

Filed: February 27, 2002

Attorney Docket: 03678.0103.CPUS00

For: **COMPOSITIONS AND METHODS  
FOR THE TREATMENT OF  
GLAUCOMA OR OCULAR  
HYPERTENSION**

**CONSENT OF ASSIGNEE TO ADD AN INVENTOR**

Commissioner for Patents  
Washington D.C. 20231

**RECEIVED**

**MAR 06 2003**

Sir:

**TECH CENTER 1600/2900**

Inspire Pharmaceuticals, Inc. is the assignee of the instant application and owns 100% interest in the application. The documentary evidence of a chain of title from the original owners to the assignee is recorded in the Patent and Trademark Office (Reel/Frame 012924/0628).

Inspire Pharmaceuticals, Inc. hereby consents to amend the instant application to add James G. Douglass, III as an inventor. The correct inventive entity is Jose L. Boyer, Benjamin R. Yerxa, Robert Plourde, Jr., Edward G. Brown, and James G. Douglass, III.

Respectfully submitted,

Date: 2/19/03

  
\_\_\_\_\_  
Inspire Pharmaceuticals, Inc.  
By: Christy Shaffer, CEO



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Jose L. BOYER, *et al.*

Appl. No. 10/087,551

Filed: February 27, 2002

For: **COMPOSITIONS AND METHODS  
FOR THE TREATMENT OF  
GLAUCOMA OR OCULAR  
HYPERTENSION**

Art Unit: 1635

Examiner: Not Yet Assigned

Attorney Docket: 03678.0103.CPUS00

STATEMENT FROM INVENTOR BEING ADDED **RECEIVED**

Commissioner for Patents  
Washington D.C. 20231


MAR 06 2003

TECH CENTER 1600/2900

Sir:

Upon review of the claims pending in the above-referenced application, I, James G. Douglass, III, believe that I am an inventor of the subject matter claimed. The error in failing to name me as an inventor in the above-referenced application arose without any deceptive intention on my part.

Date: Feb 19, 2003

  
James G. Douglass, III